JUST OUT: Global Pharma Report 2023 I Download now

DAX 40 & CH SMI 20 – a mid-year status

As the first half of 2022 ends, we wanted to take the reputational stock of the DAX 40 and CH SMI 20 indices. Both indices were among those hit hardest by a downturn in public perceptions in the first quarter of the year, and both recovered in the second quarter. This article looks at the […]